Antigen Information

General Information of This Antigen
Antigen ID
TAR0SYQPS
Antigen Name
Programmed cell death 1 ligand 1 (CD274)
Gene Name
CD274
Gene ID
29126
Synonym1
B7H1, PDCD1L1, PDCD1LG1, PDL1
Sequence1
MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNL
ELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNG
DPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLA
LTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQC
AAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACP
YNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSAN
IQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLP
DLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTV
PWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQEC
VEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARC
PSGVKPDLSYMPIWKFPDEEGACQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVG
ILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPNQAQMRILKETEL
RKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKANKEILDEAYVMAGVGSP
YVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVR
LVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT
HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWM
IDSECRPRFRELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDA
EEYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEG
AGSDVFDGDLGMGAAKGLQSLPTHDPSPLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYV
NQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ
GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV

    Click to Show/Hide
Family1
BTN/MOG family
Function1
The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function.

    Click to Show/Hide
Uniprot Entry
PD1L1_HUMAN
HGNC ID
HGNC:17635
KEGG ID
hsa:29126
Each Antibody-drug Conjuate AND It's Component Related to This Antigen
Full List of The ADC Related to This Antigen
Atezolizumab
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
Atezolizumab ADC
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 [1]
 ADC Info 
PD-L1 ADC 3
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Ala-PABC
 [1]
 ADC Info 
PDL1-Dox ADC
Doxorubicin
DNA topoisomerase 2-alpha (TOP2A)
Undisclosed
 [2]
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
PD-L1 ADC 1
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Ala-PABC
 [1]
 ADC Info 
PD-L1 ADC 2
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 [1]
 ADC Info 
ADC HE-S2
Bifunctional immunomodulator D18
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
Disulfide linker 8
 [3]
Humanized Anti-PD-L1 SGN-PDL1V mAb
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
SGN-PDL1V
Monomethyl auristatin E
Microtubule (MT)
Mc-Val-Cit-PABC
 [4]
Undisclosed
 Antibody Info 
ADC Info ADC Name Payload Target Linker Ref
 ADC Info 
YB1-ADC-PDL1
Undisclosed
Undisclosed
Undisclosed
 [5]
 ADC Info 
HLX-43
Undisclosed
Undisclosed
Undisclosed
 [6]
 ADC Info 
OX-001L ADC
Undisclosed
Undisclosed
Undisclosed
 [7]
 ADC Info 
OX-003
Undisclosed
Undisclosed
Undisclosed
 [8]
 ADC Info 
BDB-101
TLR7/8 agonist
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
Undisclosed
 [9]
 ADC Info 
PD-L1 ISA
TLR7/8 agonist
Toll-like receptor 7 (TLR7); Toll-like receptor 8 (TLR8)
Undisclosed
 [10]
References
Ref 1 Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation. Bioorg Chem. 2021 Nov;116:105366.
Ref 2 PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer. Cancers (Basel). 2019 Feb 16;11(2):232. doi: 10.3390/cancers11020232.
Ref 3 Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy. J Med Chem. 2021 Nov 11;64(21):15716-15726. doi: 10.1021/acs.jmedchem.1c00961. Epub 2021 Nov 3.
Ref 4 Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibodydrug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress). Journal of Clinical Oncology 2022 40:16_suppl, TPS3154-TPS3154.
Ref 5 YB1 pharmaceutical company product pipeline
Ref 6 Introduction to basic information on ADC drug HLX-43.
Ref 7 Harnessing novel immune escape mechanisms for cancer therapeutics: OXAB1 target validation, proof of concept and preclinical development; 2018.
Ref 8 Oxford BioTherapeutics designates second bispecific antibody program leveraging WuXi Biologics's WuXiBody platform; 2021.
Ref 9 Seven and eight biopharmaceutical company produce pipeline
Ref 10 PD-L1-targeted ISAC combines myeloid cell activation, immune checkpoint inhibition and ADCP to improve anti-tumor efficacy over anti-PD-L1 antibodies in preclinical models; 2021

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.